MARKET INTRODUCTION
Conjugate vaccines are produced through a covalent bond between a weak antigen and a strong antigen. This boosts the immune response of the host towards several diseases. Conjugate vaccines are germ specific and are competent of identifying just the targeted germs and bacteria, making them suitable as a preventive measure to provide additional protection. Conjugate vaccines are vaccines for infectious diseases.
MARKET DYNAMICS
The vaccine conjugates market is anticipated to grow in the forecast period owing to driving factors such as increasing use of conjugate vaccines for adults, rising number of regulatory approvals for conjugate vaccines, rising prevalence of diseases, and technological advancements. However, low accessibility to vaccines in remote areas and complex production procedure of conjugate vaccine are expected to restrain the growth of this market during the forecast period.
MARKET SCOPE
The "Global Vaccine Conjugates Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of vaccine conjugates market with detailed market segmentation by disease indication, type, patient stage, pathogen type, and geography. The global vaccine conjugates market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading vaccine conjugates market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global vaccine conjugates market is segmented on the basis disease indication, type, patient stage and pathogen type. Based on disease indication, the market is segmented as Pneumococcal, Influenza, Diphtheria Tetanus Pertussis and Meningococcal. Based on type, the market is segmented as Monovalent and Multivalent. Based on patient stage, the market is segmented as Pediatrics and adults. Based on Pathogen Type, the market is segmented as Bacterial, Viral and Combination.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global vaccine conjugates market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The vaccine conjugates market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting vaccine conjugates market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the vaccine conjugates market in these regions.
MARKET PLAYERS
The report covers key developments in the vaccine conjugates market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from vaccine conjugates market are anticipated to lucrative growth opportunities in the future with the rising demand for vaccine conjugates in the global market. Below mentioned is the list of few companies engaged in the Vaccine conjugates market.
The report also includes the profiles of key vaccine conjugates market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Bharat Biotech
- Biological E
- GlaxoSmithKline, plc
- Merck and Company
- Novartis AG
- Pfizer, Inc
- Sanofi Pasteur
- Serum Institute of India.
- Astellas Pharma Inc.
- Mitsubishi Tanabe Pharma Corporation
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. PUBLISHER RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Vaccine Conjugates Market - By Disease Indication
1.3.2 Vaccine Conjugates Market - By Type
1.3.3 Vaccine Conjugates Market - By Patient Stage
1.3.4 Vaccine Conjugates Market - By Pathogen Type
1.3.5 Vaccine Conjugates Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. VACCINE CONJUGATES MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. VACCINE CONJUGATES MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. VACCINE CONJUGATES MARKET - GLOBAL MARKET ANALYSIS
6.1. VACCINE CONJUGATES - GLOBAL MARKET OVERVIEW
6.2. VACCINE CONJUGATES - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. VACCINE CONJUGATES MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE INDICATION
7.1. OVERVIEW
7.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
7.3. PNEUMOCOCCAL
7.3.1. Overview
7.3.2. Pneumococcal Market Forecast and Analysis
7.4. INFLUENZA
7.4.1. Overview
7.4.2. Influenza Market Forecast and Analysis
7.5. DIPHTHERIA TETANUS PERTUSSIS
7.5.1. Overview
7.5.2. Diphtheria Tetanus Pertussis Market Forecast and Analysis
7.6. MENINGOCOCCAL
7.6.1. Overview
7.6.2. Meningococcal Market Forecast and Analysis
8. VACCINE CONJUGATES MARKET - REVENUE AND FORECASTS TO 2027 - TYPE
8.1. OVERVIEW
8.2. TYPE MARKET FORECASTS AND ANALYSIS
8.3. MONOVALENT
8.3.1. Overview
8.3.2. Monovalent Market Forecast and Analysis
8.4. MULTIVALENT
8.4.1. Overview
8.4.2. Multivalent Market Forecast and Analysis
9. VACCINE CONJUGATES MARKET - REVENUE AND FORECASTS TO 2027 - PATIENT STAGE
9.1. OVERVIEW
9.2. PATIENT STAGE MARKET FORECASTS AND ANALYSIS
9.3. PEDIATRICS
9.3.1. Overview
9.3.2. Pediatrics Market Forecast and Analysis
9.4. ADULTS
9.4.1. Overview
9.4.2. Adults Market Forecast and Analysis
10. VACCINE CONJUGATES MARKET - REVENUE AND FORECASTS TO 2027 - PATHOGEN TYPE
10.1. OVERVIEW
10.2. PATHOGEN TYPE MARKET FORECASTS AND ANALYSIS
10.3. BACTERIAL
10.3.1. Overview
10.3.2. Bacterial Market Forecast and Analysis
10.4. VIRAL
10.4.1. Overview
10.4.2. Viral Market Forecast and Analysis
10.5. COMBINATION
10.5.1. Overview
10.5.2. Combination Market Forecast and Analysis
11. VACCINE CONJUGATES MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Vaccine Conjugates Market Overview
11.1.2 North America Vaccine Conjugates Market Forecasts and Analysis
11.1.3 North America Vaccine Conjugates Market Forecasts and Analysis - By Disease Indication
11.1.4 North America Vaccine Conjugates Market Forecasts and Analysis - By Type
11.1.5 North America Vaccine Conjugates Market Forecasts and Analysis - By Patient Stage
11.1.6 North America Vaccine Conjugates Market Forecasts and Analysis - By Pathogen Type
11.1.7 North America Vaccine Conjugates Market Forecasts and Analysis - By Countries
11.1.7.1 United States Vaccine Conjugates Market
11.1.7.1.1 United States Vaccine Conjugates Market by Disease Indication
11.1.7.1.2 United States Vaccine Conjugates Market by Type
11.1.7.1.3 United States Vaccine Conjugates Market by Patient Stage
11.1.7.1.4 United States Vaccine Conjugates Market by Pathogen Type
11.1.7.2 Canada Vaccine Conjugates Market
11.1.7.2.1 Canada Vaccine Conjugates Market by Disease Indication
11.1.7.2.2 Canada Vaccine Conjugates Market by Type
11.1.7.2.3 Canada Vaccine Conjugates Market by Patient Stage
11.1.7.2.4 Canada Vaccine Conjugates Market by Pathogen Type
11.1.7.3 Mexico Vaccine Conjugates Market
11.1.7.3.1 Mexico Vaccine Conjugates Market by Disease Indication
11.1.7.3.2 Mexico Vaccine Conjugates Market by Type
11.1.7.3.3 Mexico Vaccine Conjugates Market by Patient Stage
11.1.7.3.4 Mexico Vaccine Conjugates Market by Pathogen Type
11.2. EUROPE
11.2.1 Europe Vaccine Conjugates Market Overview
11.2.2 Europe Vaccine Conjugates Market Forecasts and Analysis
11.2.3 Europe Vaccine Conjugates Market Forecasts and Analysis - By Disease Indication
11.2.4 Europe Vaccine Conjugates Market Forecasts and Analysis - By Type
11.2.5 Europe Vaccine Conjugates Market Forecasts and Analysis - By Patient Stage
11.2.6 Europe Vaccine Conjugates Market Forecasts and Analysis - By Pathogen Type
11.2.7 Europe Vaccine Conjugates Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Vaccine Conjugates Market
11.2.7.1.1 Germany Vaccine Conjugates Market by Disease Indication
11.2.7.1.2 Germany Vaccine Conjugates Market by Type
11.2.7.1.3 Germany Vaccine Conjugates Market by Patient Stage
11.2.7.1.4 Germany Vaccine Conjugates Market by Pathogen Type
11.2.7.2 France Vaccine Conjugates Market
11.2.7.2.1 France Vaccine Conjugates Market by Disease Indication
11.2.7.2.2 France Vaccine Conjugates Market by Type
11.2.7.2.3 France Vaccine Conjugates Market by Patient Stage
11.2.7.2.4 France Vaccine Conjugates Market by Pathogen Type
11.2.7.3 Italy Vaccine Conjugates Market
11.2.7.3.1 Italy Vaccine Conjugates Market by Disease Indication
11.2.7.3.2 Italy Vaccine Conjugates Market by Type
11.2.7.3.3 Italy Vaccine Conjugates Market by Patient Stage
11.2.7.3.4 Italy Vaccine Conjugates Market by Pathogen Type
11.2.7.4 Spain Vaccine Conjugates Market
11.2.7.4.1 Spain Vaccine Conjugates Market by Disease Indication
11.2.7.4.2 Spain Vaccine Conjugates Market by Type
11.2.7.4.3 Spain Vaccine Conjugates Market by Patient Stage
11.2.7.4.4 Spain Vaccine Conjugates Market by Pathogen Type
11.2.7.5 United Kingdom Vaccine Conjugates Market
11.2.7.5.1 United Kingdom Vaccine Conjugates Market by Disease Indication
11.2.7.5.2 United Kingdom Vaccine Conjugates Market by Type
11.2.7.5.3 United Kingdom Vaccine Conjugates Market by Patient Stage
11.2.7.5.4 United Kingdom Vaccine Conjugates Market by Pathogen Type
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Vaccine Conjugates Market Overview
11.3.2 Asia-Pacific Vaccine Conjugates Market Forecasts and Analysis
11.3.3 Asia-Pacific Vaccine Conjugates Market Forecasts and Analysis - By Disease Indication
11.3.4 Asia-Pacific Vaccine Conjugates Market Forecasts and Analysis - By Type
11.3.5 Asia-Pacific Vaccine Conjugates Market Forecasts and Analysis - By Patient Stage
11.3.6 Asia-Pacific Vaccine Conjugates Market Forecasts and Analysis - By Pathogen Type
11.3.7 Asia-Pacific Vaccine Conjugates Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Vaccine Conjugates Market
11.3.7.1.1 Australia Vaccine Conjugates Market by Disease Indication
11.3.7.1.2 Australia Vaccine Conjugates Market by Type
11.3.7.1.3 Australia Vaccine Conjugates Market by Patient Stage
11.3.7.1.4 Australia Vaccine Conjugates Market by Pathogen Type
11.3.7.2 China Vaccine Conjugates Market
11.3.7.2.1 China Vaccine Conjugates Market by Disease Indication
11.3.7.2.2 China Vaccine Conjugates Market by Type
11.3.7.2.3 China Vaccine Conjugates Market by Patient Stage
11.3.7.2.4 China Vaccine Conjugates Market by Pathogen Type
11.3.7.3 India Vaccine Conjugates Market
11.3.7.3.1 India Vaccine Conjugates Market by Disease Indication
11.3.7.3.2 India Vaccine Conjugates Market by Type
11.3.7.3.3 India Vaccine Conjugates Market by Patient Stage
11.3.7.3.4 India Vaccine Conjugates Market by Pathogen Type
11.3.7.4 Japan Vaccine Conjugates Market
11.3.7.4.1 Japan Vaccine Conjugates Market by Disease Indication
11.3.7.4.2 Japan Vaccine Conjugates Market by Type
11.3.7.4.3 Japan Vaccine Conjugates Market by Patient Stage
11.3.7.4.4 Japan Vaccine Conjugates Market by Pathogen Type
11.3.7.5 South Korea Vaccine Conjugates Market
11.3.7.5.1 South Korea Vaccine Conjugates Market by Disease Indication
11.3.7.5.2 South Korea Vaccine Conjugates Market by Type
11.3.7.5.3 South Korea Vaccine Conjugates Market by Patient Stage
11.3.7.5.4 South Korea Vaccine Conjugates Market by Pathogen Type
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Vaccine Conjugates Market Overview
11.4.2 Middle East and Africa Vaccine Conjugates Market Forecasts and Analysis
11.4.3 Middle East and Africa Vaccine Conjugates Market Forecasts and Analysis - By Disease Indication
11.4.4 Middle East and Africa Vaccine Conjugates Market Forecasts and Analysis - By Type
11.4.5 Middle East and Africa Vaccine Conjugates Market Forecasts and Analysis - By Patient Stage
11.4.6 Middle East and Africa Vaccine Conjugates Market Forecasts and Analysis - By Pathogen Type
11.4.7 Middle East and Africa Vaccine Conjugates Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Vaccine Conjugates Market
11.4.7.1.1 South Africa Vaccine Conjugates Market by Disease Indication
11.4.7.1.2 South Africa Vaccine Conjugates Market by Type
11.4.7.1.3 South Africa Vaccine Conjugates Market by Patient Stage
11.4.7.1.4 South Africa Vaccine Conjugates Market by Pathogen Type
11.4.7.2 Saudi Arabia Vaccine Conjugates Market
11.4.7.2.1 Saudi Arabia Vaccine Conjugates Market by Disease Indication
11.4.7.2.2 Saudi Arabia Vaccine Conjugates Market by Type
11.4.7.2.3 Saudi Arabia Vaccine Conjugates Market by Patient Stage
11.4.7.2.4 Saudi Arabia Vaccine Conjugates Market by Pathogen Type
11.4.7.3 U.A.E Vaccine Conjugates Market
11.4.7.3.1 U.A.E Vaccine Conjugates Market by Disease Indication
11.4.7.3.2 U.A.E Vaccine Conjugates Market by Type
11.4.7.3.3 U.A.E Vaccine Conjugates Market by Patient Stage
11.4.7.3.4 U.A.E Vaccine Conjugates Market by Pathogen Type
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Vaccine Conjugates Market Overview
11.5.2 South and Central America Vaccine Conjugates Market Forecasts and Analysis
11.5.3 South and Central America Vaccine Conjugates Market Forecasts and Analysis - By Disease Indication
11.5.4 South and Central America Vaccine Conjugates Market Forecasts and Analysis - By Type
11.5.5 South and Central America Vaccine Conjugates Market Forecasts and Analysis - By Patient Stage
11.5.6 South and Central America Vaccine Conjugates Market Forecasts and Analysis - By Pathogen Type
11.5.7 South and Central America Vaccine Conjugates Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Vaccine Conjugates Market
11.5.7.1.1 Brazil Vaccine Conjugates Market by Disease Indication
11.5.7.1.2 Brazil Vaccine Conjugates Market by Type
11.5.7.1.3 Brazil Vaccine Conjugates Market by Patient Stage
11.5.7.1.4 Brazil Vaccine Conjugates Market by Pathogen Type
11.5.7.2 Argentina Vaccine Conjugates Market
11.5.7.2.1 Argentina Vaccine Conjugates Market by Disease Indication
11.5.7.2.2 Argentina Vaccine Conjugates Market by Type
11.5.7.2.3 Argentina Vaccine Conjugates Market by Patient Stage
11.5.7.2.4 Argentina Vaccine Conjugates Market by Pathogen Type
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. VACCINE CONJUGATES MARKET, KEY COMPANY PROFILES
13.1. BHARAT BIOTECH
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BIOLOGICAL E
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. GLAXOSMITHKLINE, PLC
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. MERCK AND COMPANY
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. NOVARTIS AG
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. PFIZER, INC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. SANOFI PASTEUR
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. SERUM INSTITUTE OF INDIA
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. ASTELLAS PHARMA INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. MITSUBISHI TANABE PHARMA CORPORATION
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT PUBLISHER
14.2. GLOSSARY OF TERMS
The List of Companies
1.Bharat Biotech
2.Biological E
3.GlaxoSmithKline, plc
4.Merck and Company
5.Novartis AG
6.Pfizer, Inc
7.Sanofi Pasteur
8.Serum Institute of India
9.Astellas Pharma Inc.
10.Mitsubishi Tanabe Pharma Corporation
Vinpocetine Drugs Market Forecast to 202..
MARKET INTRODUCTION
Vinpocetine (ethyl apovincaminate) is a..
+1-646-791 7070US (Toll Free)